Neurostimulation for Spinal Cord Injury
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to learn more about the connections between the brain, nerves, and diaphragm after experiencing a cervical spinal cord injury (SCI).The main question it aims to answer is: Changes in respiratory function and recovery using stimulation and respiratory exercise training in spinal cord-injured individuals. Participants will complete a maximum of 55 study visits. They will be asked to complete about 40 treatment sessions which include multiple stimulation sessions over the scalp and neck, followed by about 60 minutes of respiratory training. Assessment sessions will be completed prior at baseline, after 20 sessions and after 40 sessions of study treatment.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications, specifically Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or drugs that prolong the PR Interval. If you are on any of these, you would need to stop them to participate.
What data supports the effectiveness of the treatment Neurostimulation for Spinal Cord Injury?
Research shows that various forms of electrical stimulation, such as epidural and transcutaneous stimulation, can help improve movement and reduce pain in people with spinal cord injuries. For example, studies have found that these treatments can lead to better walking ability, increased muscle strength, and significant pain relief in many patients.12345
Is neurostimulation generally safe for humans?
Neurostimulation, including various forms like electrical stimulation and epidural electrical stimulation, is generally considered safe when proper precautions are taken. However, there are risks such as tissue burns and neurologic injury, which can be minimized by following safety guidelines, ensuring proper electrode placement, and using appropriate equipment. In some cases, like with an infant with spina bifida, electrical stimulation was found to be safe and well tolerated over a 12-month period.678910
How does the treatment Neurostimulation for Spinal Cord Injury differ from other treatments for this condition?
Neurostimulation for Spinal Cord Injury is unique because it uses electrical stimulation techniques, such as epidural and transcutaneous spinal cord stimulation, to activate and retrain spinal circuits, which can improve motor functions and respiratory control. Unlike traditional treatments, this approach directly targets the spinal cord to promote regeneration and functional recovery, offering a novel method for rehabilitation in patients with spinal cord injuries.2391112
Research Team
Monica Perez, PhD
Principal Investigator
Shirley Ryan AbilityLab
Eligibility Criteria
This trial is for adults aged 18-85 with a cervical spinal cord injury at C1-C5 level, at least 6 months post-injury. They must have respiratory deficits and either use mechanical ventilation or have vital capacity less than 80% predicted. A family member or caregiver must be able to operate the ventilator during visits. Exclusions include dependence on diaphragmatic pacer, certain medications, brain injuries, seizures, pregnancy, metal in skull, other major illnesses or conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo 40 treatment sessions including multiple stimulation sessions over the scalp and neck, followed by about 60 minutes of respiratory training
Assessment
Assessment sessions are completed at baseline, after 20 sessions, and after 40 sessions of study treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Neurostimulation
- Respiratory training
Neurostimulation is already approved in United States, European Union for the following indications:
- Respiratory dysfunction in spinal cord injury patients
- Respiratory failure in spinal cord injury patients
- Neuropathic pain relief
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shirley Ryan AbilityLab
Lead Sponsor